News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Merck Sharp and Dohme LLC, (a subsidiary of Merck & Co. Inc., Rahway, New Jersey, USA)/ “A phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis.

Study Status:

Open for enrollment

Contact Information:

(956) 362-8074

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

This research trial is testing an experimental drug called MK-3655 in people with liver disease called nonalcoholic steatohepatitis (NASH).


Principal Investigator
Fernando Membreno, MD
Hiram Garcia Jr.
Merck, Sharp, and Dohme LLC.
Type of Trial
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram